Holen Sie sich die Stockscreener-App
13.75
0.72%
-0.10
Vorhandelsmarkt:
13.77
0.02
+0.15%
Schlusskurs vom Vortag:
$13.85
Offen:
$13.86
24-Stunden-Volumen:
726.97K
Relative Volume:
0.56
Marktkapitalisierung:
$1.15B
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-231.96M
KGV:
-4.3469
EPS:
-3.1632
Netto-Cashflow:
$-243.39M
1W Leistung:
+2.08%
1M Leistung:
+2.61%
6M Leistung:
+24.83%
1J Leistung:
+100.44%
1-Tages-Spanne:
$13.31
$14.07
1-Wochen-Bereich:
$12.53
$14.07
52-Wochen-Spanne:
$5.30
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.75 | 1.16B | 31.37M | -231.96M | -243.39M | -3.1632 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
Eyepoint Pharma earnings up next as burn rate takes focus - Investing.com
How The EyePoint (EYPT) Story Is Shifting With DURAVYU And Phase 3 DME Trials - Yahoo Finance
MSN Money - MSN
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com
EyePoint Inc (EYPT) - MSN
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Earnings Preview: EyePoint to Report Financial Results Pre-market on May 06 - Moomoo
Is EyePoint (NASDAQ:EYPT) In A Good Position To Invest In Growth? - Moomoo
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - The Manila Times
Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday - MarketBeat
EyePoint (NASDAQ: EYPT) plans virtual 2026 meeting and larger equity pool - Stock Titan
EyePoint, Inc. Income Statement – NASDAQ:EYPT - TradingView
EYPT (EyePoint Inc.) shares rise 2.02 percent despite wider Q4 2025 loss and 27.5 percent year over year revenue drop.Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Top Executive Makes Strategic Move With EyePoint Pharmaceuticals Stock - TipRanks
Understanding Momentum Shifts in (EYPT) - Stock Traders Daily
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares By Investing.com - Investing.com South Africa
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares - Investing.com
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
Is EyePoint (EYPT) stock reversing trend (Bullish Sentiment) 2026-04-20Community Volume Signals - Xã Thanh Hà
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
[144] EyePoint, Inc. SEC Filing - Stock Titan
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 150% Potential Upside in the Booming Biotech Sector - DirectorsTalk Interviews
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Eyepoint reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
EyePoint hires 14 employees, grants 362,500 stock options - Stock Titan
JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway - TipRanks
EyePoint posts April 2026 investor presentation; DURAVYU Phase 3 updates, cash runway into Q4 2027 - TradingView
DURAVYU Phase 3 plans and cash runway outlined by EyePoint (EYPT) - Stock Titan
Will EyePoint (EYPT) Stock Miss Expectations | Price at $14.00, Down 1.34%Stock Entry Points - Xã Thanh Hà
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (EYPT) Movement - Stock Traders Daily
Recap Report: What is the long term forecast for EyePoint Pharmaceuticals Inc stockQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Stocks to watch: EyePoint sees relative strength rating rise to 92 - MSN
What are analysts saying about EyePoint (EYPT) Stock | Price at $13.57, Up 3.51%Community Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Aug Reactions: What are analysts price targets for EyePoint Pharmaceuticals IncPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7%Time to Sell? - marketbeat.com
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com
EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK
Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
STU:PV3B PB Ratio: 3.51 — 21% Below Median - GuruFocus
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com
EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):